Chosa Oncology (CHOSA) Q3 2025 earnings summary

Executive summary

• Achieved significant scientific and strategic progress in Q3 2025, gaining international recognition for robust clinical data and expanding global partnerships.

• Positive results from collaboration with ETOP/EORTC validated Platin-DRP® for predicting response to both cisplatin and carboplatin in NSCLC.

• Presented new data at ESMO 2025 showing Platin-DRP® predicts carboplatin benefit in metastatic breast cancer.

• Won the 2025 Jiangning International Entrepreneurship Contest in China, enhancing global profile and opening Asian market opportunities.

Financial highlights

• Q3 2025 result after financial items: -2,541 TSEK (Q3 2024: -1,864 TSEK).

• Earnings per share: -0.032 SEK (Q3 2024: -0.31 SEK).

• Equity ratio at 94% (Q3 2024: 88%).

• Cash and cash equivalents at September 30, 2025: 2,657 TSEK (Q3 2024: 9,939 TSEK).

• Group result for Q3: -1,703 TSEK (Q3 2024: -5,291 TSEK).

Outlook and guidance

• Focus remains on regulatory and commercial development of Platin-DRP® as an FDA- and CE-approved diagnostic in the US and Europe.

• Continued strategic collaborations with academic groups, diagnostics, and pharma companies to drive commercialization.